Type 2 Diabetes

Scott Kahan, MD, MPH, discusses the shortcomings of the current staging systems used for overweight and obesity and recommends the use of weight-related health and functional status in addition to BMI.

Further adding to the discussion surrounding the impact of endocrine-disrupting chemicals, an analysis of data from the SWAN Multipollutant Study suggests increased exposure to phthlates was linked to a 30-63% increase in risk of developing diabetes among White women in midlife.

Leveraging data from the Tromsø study, the D2d study, and the DPVD study, a systematic review and meta-analysis concluded vitamin D supplementation could help reduce risk of progression to diabetes by 15% among people with prediabetes.

A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.

Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.

The risk of diabetes was reduced by approximately 50% in both the vigorous and moderate aerobic exercise groups compared with the nonexercise group.

A ED screening program identified a substantial number of patients with undiagnosed prediabetes and T2D or undermanaged disease, particularly racial and ethnic minorities.

Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.

An analysis of 2 decades worth of data from the Clinical Practice Research Datalink suggests all-cause mortality rates in type 2 diabetes have decreased but sheds light on upward trends in mortality from multiple different forms of cancer, including pancreatic, liver, and lung cancer, particularly among older patients.

Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

In their final episode from the ADCES 2nd Annual Diabetes Technology Conference, our hosts are joined by Gary Scheiner, MS, and Jennifer Okemah, RD, to discuss their businesses, a glimpse into their personal journeys into becoming diabetes care and education specialists, and how they have seen their role in improving care transform in recent years.

An analysis of patient data from the REGARDS cohort suggests the increase in relative risk observed with traditional risk factors, such as hypertension and diabetes, on risk of stroke decreases as patients age, but investigators point out this does not diminish the importance of addressing these risk factors.

The uptake of modern glucose-monitoring technologies for people with T1D and T2D may be dependent on out-of-pocket costs, suggesting the need to reconsider cost-benefit profiles of these devices.

A higher exposure to both foods and water-originated and additives-originated nitrites was associated with higher T2D risk, showing no potential benefits of their use.

The 2022 updated guidelines includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease.

An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.

A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.

Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.

Higher preoperative visual acuity in patients with dTRD was associated with higher vision after PPV, suggesting the importance of early intervention.

Kimberly Simmons, MD, provides resources for patients with T1D, and key takeaways for pediatricians screening for and diagnosing T1D in pediatric patients.

Tina Q. Tan, MD, and Kimberly Simmons, MD, discuss improved methods of monitoring blood glucose levels in patients with type 1 diabetes.

Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.

Results from the REGARDS study suggest traditional CKD risk factors were associated with higher risk of incident CKD and eGFR decline in Black individuals, compared to White individuals.

Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.

A systematic review and meta-analysis of observational studies of people with diabetes suggest more than 1-in-4 also had a diagnosis of osteoporosis.

MAFLD-lean and MAFLD-diabetes subgroups recorded a higher risk of all-cause and disease-specific mortality compared to the MAFLD-overweight/obese group.

Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.

Using data from more than 55,000 people with diabetes using metformin is providing new insight into the apparent reductions in risk of negative cardiovascular and renal outcomes as well as all-cause mortality with use of SGLT2 inhibitors.